Simultaneous quantification of co-administered trastuzumab and pertuzumab in serum based on nano-surface and molecular-orientation limited (nSMOL) proteolysis-Reference-Cited by-同舟云学术

Simultaneous quantification of co-administered trastuzumab and pertuzumab in serum based on nano-surface and molecular-orientation limited (nSMOL) proteolysis

Published:2024 Issue:27 Volume:14 Page:19550-19559
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Liu Liang¹^ORCID,Sun Bo²,Cai Junlong³,Wang Jiajun¹,Liu Wei⁴^ORCID,Hu Hankun¹,Chen Siyi¹,Wu Jianhua¹

Affiliation:

1. Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan University, 169 Donghu Road, Wuchang District, Wuhan 430071, China

2. Department of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, 222000, China

3. Department of Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

4. Key Laboratory of Artificial Micro- and Nano-Structures of Ministry of Education, School of Physics and Technology, Wuhan University, Wuhan, 430072, China

Abstract

Monoclonal antibodies (mAbs) are pivotal therapeutic agents for various diseases, and effective treatment hinges on attaining a specific threshold concentration of mAbs in patients.

Funder

Chinese Pharmaceutical Association

China International Medical Foundation

National Natural Science Foundation of China

Natural Science Foundation of Hubei Province

Zhongnan Hospital of Wuhan University

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA03060E

Reference28 articles.

1. Biopharmaceutical benchmarks 2022

2. Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

3. Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD

4. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases

5. Resistance to Trastuzumab